Famciclovir

Overview

Famciclovir (Famvir®) is an oral antiviral medication most commonly used in veterinary medicine for the management of feline herpesvirus type 1 (FHV-1) infections. It is considered one of the more useful systemic antiviral options for cats with herpetic ocular or upper respiratory disease and is generally well tolerated during short-term treatment courses.

In clinical use, famciclovir may help reduce viral shedding and improve signs such as conjunctivitis, keratitis, ocular discharge, sneezing, and respiratory irritation associated with FHV-1 infection. It controls viral replication but does not eliminate latent herpesvirus infection, so recurrence of disease may still occur during periods of stress or immunosuppression.

Famciclovir is a prodrug that is converted in the body to penciclovir, the active antiviral metabolite. Cats convert famciclovir to penciclovir inefficiently because they are deficient in aldehyde oxidase, the liver enzyme that completes the conversion, so data from other species cannot be extrapolated and feline dosing recommendations have evolved over time.

Mechanism of Action (MOA): After conversion to penciclovir, the drug is phosphorylated within herpesvirus-infected cells and then inhibits viral DNA polymerase. This interferes with viral DNA synthesis and slows replication of susceptible herpesviruses. Famciclovir is considered virostatic rather than virucidal, meaning it suppresses replication rather than permanently eradicating the virus.

Indications

Famciclovir is primarily used in cats for the management of feline herpesvirus type 1 (FHV-1) infections, particularly when clinical disease is moderate to severe, recurrent, or associated with ocular involvement. It is used to reduce viral replication and improve clinical comfort but does not cure latent infection.

• Feline herpesvirus upper respiratory disease: May help in FHV-1-associated rhinosinusitis and upper respiratory disease.
• Herpetic conjunctivitis: Used in cats with FHV-1-associated conjunctivitis.
• Herpetic keratitis / corneal disease: May be beneficial in FHV-1-associated ulcerative or nonulcerative keratitis.
• Recurrent herpesvirus flare-ups: Often considered in cats with recurrent FHV-1 exacerbations, which can become more severe at times of stress or immunocompromise.
• Shelter / multi-cat environments: Shelter cats have been dosed within the studied dosage range, 40–90 mg/kg twice daily for up to 21 days, where reduction of conjunctival shedding is clinically desirable; a single dose or 7-day course did not improve clinical signs, although the 7-day course reduced conjunctival FHV-1 shedding.
• Alternative to intensive topical antivirals: Systemic therapy may reduce the need for frequent ocular antiviral drops in some patients, although supportive topical therapy may still be necessary.
• May be used for FHV-1-associated dermatitis, at the same 40–90 mg/kg every 12 hours used for ocular and respiratory disease.

Dosage (Reference)

Dog

No established or routinely recommended canine dosage was identified. Famciclovir is not commonly used in dogs in veterinary practice, and published dosing guidance for canine patients is lacking.

Cat

Famciclovir is used extra-label in cats for feline herpesvirus type 1 (FHV-1). Dose recommendations have evolved over time, and higher dosing regimens appear more reliable for achieving therapeutic penciclovir concentrations, particularly in ocular tissues.

Warnings & Precautions

Famciclovir is generally well tolerated in cats when used appropriately, but treatment should still be individualized and monitored carefully. Most veterinary experience involves feline herpesvirus therapy, and precautions are based on available feline data, human prescribing information, and general antiviral use principles.

• Hypersensitivity: Contraindicated in patients with known hypersensitivity to famciclovir or penciclovir.
• Renal dysfunction: Use cautiously in patients with kidney disease.
• Renal dysfunction: Human dose reductions are recommended when creatinine clearance falls below 60 mL/min; in cats with renal insufficiency the dose should be reduced or the dosing frequency extended, with careful monitoring.
• Do not confuse with acyclovir: Medication name confusion can occur.
• Do not substitute valacyclovir: it should never be used in cats. FHV-1 is also resistant to acyclovir and valacyclovir, so neither is an effective alternative.
• Not a cure for herpesvirus: Famciclovir suppresses viral replication during active disease but does not eliminate latent infection Recurrence may still occur during stress or immunosuppression.
• Variable feline pharmacokinetics: Cats metabolize famciclovir differently from many species, and drug exposure may not increase proportionally with dose.
• Variable feline pharmacokinetics: Use established feline protocols rather than extrapolating from other animals.
• Long-term therapy: If prolonged or repeated treatment is required, obtain a baseline CBC, electrolytes and a renal panel including BUN and creatinine, with urinalysis and periodic rechecks during chronic dosing.
• Pregnancy and nursing: In laboratory animals, doses up to 1000 mg/kg/day caused no observed effects on developing embryos or fetuses. Penciclovir is excreted into rat milk at concentrations 8 times higher than in plasma; safety in pregnant or lactating dogs and cats remains unestablished Use only when expected benefit outweighs potential reproductive or neonatal risk.
• Male fertility concerns: Dose-related testicular toxicity — reduced and abnormal sperm and seminiferous tubule atrophy — with reduced male fertility has been reported in laboratory animals at high exposures; no effect on females was observed. Relevance to clinical veterinary use is uncertain but should be considered in breeding animals.
• Persistent ocular disease: Cats with severe corneal ulcers, chronic pain, or vision-threatening disease may require additional ophthalmic therapy beyond oral antiviral treatment.
• Administration adherence: Missed doses or premature discontinuation may reduce treatment success, particularly during active flare-ups.

Drug Interactions

Published veterinary interaction data for famciclovir are limited. Most clinically relevant concerns are based on human data or theoretical effects involving its active metabolite, penciclovir. Medication history should be reviewed carefully, especially in cats receiving chronic or multi-drug therapy.

• Probenecid: May reduce renal excretion of penciclovir and increase plasma concentrations, potentially increasing the risk of adverse effects.
• Nephrotoxic medications: Reduce the famciclovir dose in patients with compromised renal function.
• Other antivirals: FHV-1 is resistant to acyclovir and valacyclovir; famciclovir is the most promising oral antiviral for affected cats.

Side Effects & Overdose

Side Effects

Famciclovir is usually well tolerated in cats when used for short treatment courses, but adverse effects can occur. Reported veterinary effects are primarily gastrointestinal or behavioral, while additional reactions are extrapolated from human experience.

• Adverse effects were reported in about 17% of cats in one study.
• Diarrhea: The most frequently reported adverse effect in treated cats, seen in about 7% in one study; gastrointestinal signs are the commonest problem overall.
• Polydipsia: Increased water intake was reported in about 5% of cats during therapy.
• Vomiting: Mild gastrointestinal upset may occur, reported in about 1.7% of cats; giving the dose with a small amount of food may help.
• Reduced appetite / weight loss: Temporary inappetence is among the effects most frequently seen in cats, and weight loss was reported in about 1.7%.
• Hiding behavior / lethargy: Hiding behaviour was reported in about 1.7% of treated cats; some may simply appear quieter or less interactive.
• Pruritus or hypersensitivity: Pruritus has been reported in people; the frequency in cats is unknown.
• Laboratory abnormalities: Mild anaemia and a mild increase in white blood cells have been observed in cats. Neutropenia, electrolyte disturbances and increased liver enzymes have been reported in humans.
• Renal concerns: In people, renal failure has occurred particularly when doses were not adjusted for renal dysfunction; veterinary significance is uncertain.

Overdose

Limited overdose information is available in dogs and cats. Supportive treatment is recommended.  

• Dialysis: Penciclovir can be removed by haemodialysis.
• After a known or suspected overdose, consult a 24-hour poison control centre that provides veterinary-specific advice.

Key Notes

Practical clinical points that may help optimize the effective use of famciclovir in cats:

• Early intervention matters: Famciclovir may shorten the course and severity of active FHV-1 disease.
• Best suited for feline patients: In everyday veterinary practice, famciclovir use is focused mainly on cats, particularly for ocular and upper respiratory herpesvirus disease.
• Clinical response may be gradual: Treatment courses of 2 to 4 weeks are often suggested.
• Stress reduction supports control: Minimizing stress may help reduce exacerbations in cats with herpetic disease.
• Hydration and nutrition are important: Cats with nasal congestion may eat poorly, so appetite support and hydration can strongly influence recovery.
• Chronic eye cases need reassessment: Recurrent corneal disease or persistent conjunctivitis may require ophthalmic examination for scarring, sequestrum, or secondary bacterial disease.
• Tablet planning improves compliance: The film-coated tablets may be split. A 100 mg/mL suspension can be prepared by mixing twenty 500 mg tablets with 100 mL of a 1:1 Ora-Plus/Ora-Sweet mixture; refrigerate for up to 90 days and shake well before use. Other compounded formulations have not shown consistent quality or strength.
• Track flare patterns: Most affected cats become chronic carriers, and exacerbations may be more severe during stress or immunocompromise.
• Penciclovir bioavailability after oral famciclovir in cats is about 7–13% and varies between individuals; pharmacokinetics are non-linear and the elimination half-life is approximately 4 to 5 hours.
• Penciclovir reaches the tear film, and concentrations were significantly higher on 90 mg/kg dosing, peaking at about 25% of plasma levels — the basis for preferring the higher dose in ocular herpesvirus disease.
• Viral resistance can occur through mutation of viral thymidine kinase or viral DNA polymerase.
• pharmacokinetic study found no significant increase in peak concentration or total exposure across 62.5–93.75 mg/kg; increasing the dose within this studied range did not contribute to therapeutic efficacy.
• Shelter evidence is mixed: a single dose or 7-day course did not improve clinical signs, although the 7-day course reduced conjunctival shedding; a later randomised trial using 40–90 mg/kg twice daily for up to 21 days found a lower risk of worsening clinical signs.
• Store tablets at room temperature in an airtight, light-resistant container.